CPI-613, a lipoic acid analog, selectively inhibits pyruvate dehydrogenase and α-ketoglutarate dehydrogenase/2-oxoglutarate dehydrogenase (OGDH) in tumor cells, resulting in disruption of the Krebs cycle and ultimately leading to selective tumor cell death.12 Here, OGDH is linked to neoplasm.